InterMune CEO: Bittersweet ending to biotech’s comeback story
August 25, 2014 at 02:09 AM EDT
InterMune Inc.’s comeback story — from a drug rejection by the FDA to an $8.3 billion buyout offer Sunday from drug giant Roche — is mixed for Dan Welch...
